Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07229417 · ClinicalTrials.gov registry record · Phase 2
IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma
A Phase 2 study of Metastatic Endocrine Refractory and Triple Negative Invasive Lobular Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT07229417: Recruiting Phase 2 study of Metastatic Endocrine Refractory and Triple Negative Invasive Lobular Carcinoma, sponsored by M.D. Anderson Cancer Center.
NCT07229417 is a Phase 2 study of Metastatic Endocrine Refractory and Triple Negative Invasive Lobular Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 29 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07229417, a Phase 2 study of Metastatic Endocrine Refractory and Triple Negative Invasive Lobular Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if ivonescimab can help to control endocrine-refractory HR+ HER2- and/or TN mILC.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- DRUG Ivonescimab
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2025-10-22 |
| Est. Completion | 2029-09-30 |
| Phase | Phase 2 |
What NCT07229417 shows while recruiting
NCT07229417 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with Metastatic Endocrine Refractory appearing as the primary indexed condition, and to 1 intervention - of which Ivonescimab is the first listed.
NCT07229417 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07229417 about?
NCT07229417 is a clinical study titled "IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma". To learn if ivonescimab can help to control endocrine-refractory HR+ HER2- and/or TN mILC.
What is the current status of trial NCT07229417?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2025-10-22. Estimated completion is 2029-09-30.
What conditions does trial NCT07229417 study?
This clinical trial studies the following conditions: Metastatic Endocrine Refractory, Triple Negative Invasive Lobular Carcinoma.
What interventions are being tested in trial NCT07229417?
The interventions under investigation include: Ivonescimab (DRUG).
Who is sponsoring clinical trial NCT07229417?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07229417 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07229417's enrollment target sits among peer trials
29 1669th of 2000 higher than 325 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI